Daclizumab (Zinbryta).

Daclizumab (Zinbryta).

Show other versions (1)

The objective of this systematic review is to examine the beneficial and harmful effects of Daclizumab (DAC) subcutaneously (SC) in the treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients.

Saved in:

Bibliographic Details
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK535191/ Full text
Format:	Electronic eBook
Language:	English
Published:	[Ottawa, Ontario] : Canadian Agency for Drugs and Technologies in Health, 2017
Series:	Common drug review clinical review report.
Subjects:	Multiple Sclerosis, Relapsing-Remitting > drug therapy. Daclizumab > therapeutic use. Daclizumab > adverse effects. Drug Evaluation. Treatment Outcome. Canada. Systematic Review. Tables.

Description
Summary:	The objective of this systematic review is to examine the beneficial and harmful effects of Daclizumab (DAC) subcutaneously (SC) in the treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients.
Physical Description:	1 online resource (1 PDF file (ix, 113 pages)) : illustrations.
Source of Description, Etc. Note:	Description based on online resource; title from PDF title page (viewed March 5, 2019).